BACKGROUND: Patients with ductal carcinoma in situ (DCIS) are at increased risk for developing contralateral breast cancer (CBC). Consequently, more women with DCIS are electing to undergo contralateral prophylactic mastectomy (CPM). We evaluated factors associated with CPM in patients with DCIS who underwent genetic counseling for BRCA testing. METHODS: This retrospective study involved 165 women with DCIS referred for genetic counseling between 2003 and 2011. Patient characteristics were age, marital and educational status, tumor markers, nuclear grade, family history of breast cancer (BC) and ovarian cancer (OC), race, Ashkenazi Jewish ancestry, and BRCA results. Univariate and multivariate logistic regression analyses were used to determine predictive factors associated with CPM election. RESULTS: Of 165 patients, 44 (27 %) underwent CPM. Patients <45 years of age were more likely to elect CPM (p = 0.0098). A BRCA+ mutation was found in 17 patients (10.3 %), and BRCA+ women were more likely to elect CPM than BRCA or untested women (p = 0.0001). Patients who had a family history of OC (57.7 %) were more likely to choose CPM than those with no family history (p = 0.0004). Younger age, BRCA+, and an OC family history remained significant in the multivariate model (p < 0.008). CONCLUSION: The CPM rate among patients with DCIS who undergo genetic counseling is high. Factors associated with increased likelihood of CPM among this group were age, BRCA+, and a family history of OC. Further studies are needed to evaluate patients' perceptions of CBC risk and their role in the likelihood of CPM choice.
BACKGROUND:Patients with ductal carcinoma in situ (DCIS) are at increased risk for developing contralateral breast cancer (CBC). Consequently, more women with DCIS are electing to undergo contralateral prophylactic mastectomy (CPM). We evaluated factors associated with CPM in patients with DCIS who underwent genetic counseling for BRCA testing. METHODS: This retrospective study involved 165 women with DCIS referred for genetic counseling between 2003 and 2011. Patient characteristics were age, marital and educational status, tumor markers, nuclear grade, family history of breast cancer (BC) and ovarian cancer (OC), race, Ashkenazi Jewish ancestry, and BRCA results. Univariate and multivariate logistic regression analyses were used to determine predictive factors associated with CPM election. RESULTS: Of 165 patients, 44 (27 %) underwent CPM. Patients <45 years of age were more likely to elect CPM (p = 0.0098). A BRCA+ mutation was found in 17 patients (10.3 %), and BRCA+women were more likely to elect CPM than BRCA or untested women (p = 0.0001). Patients who had a family history of OC (57.7 %) were more likely to choose CPM than those with no family history (p = 0.0004). Younger age, BRCA+, and an OC family history remained significant in the multivariate model (p < 0.008). CONCLUSION: The CPM rate among patients with DCIS who undergo genetic counseling is high. Factors associated with increased likelihood of CPM among this group were age, BRCA+, and a family history of OC. Further studies are needed to evaluate patients' perceptions of CBC risk and their role in the likelihood of CPM choice.
Authors: Rosalinda Alvarado; Sara A Lari; Robert E Roses; Benjamin D Smith; Wei Yang; Elizabeth A Mittendorf; Banu K Arun; Anthony Lucci; Gildy V Babiera; Jamie L Wagner; Abigail S Caudle; Funda Meric-Bernstam; Rosa F Hwang; Isabelle Bedrosian; Kelly K Hunt; Henry M Kuerer Journal: Ann Surg Oncol Date: 2012-05-24 Impact factor: 5.344
Authors: H Meijers-Heijboer; B van Geel; W L van Putten; S C Henzen-Logmans; C Seynaeve; M B Menke-Pluymers; C C Bartels; L C Verhoog; A M van den Ouweland; M F Niermeijer; C T Brekelmans; J G Klijn Journal: N Engl J Med Date: 2001-07-19 Impact factor: 91.245
Authors: L L Montgomery; K N Tran; M C Heelan; K J Van Zee; M J Massie; D K Payne; P I Borgen Journal: Ann Surg Oncol Date: 1999-09 Impact factor: 5.344
Authors: D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman Journal: Am J Hum Genet Date: 1998-03 Impact factor: 11.025
Authors: Thomas S Frank; Amie M Deffenbaugh; Julia E Reid; Mark Hulick; Brian E Ward; Beth Lingenfelter; Kathi L Gumpper; Thomas Scholl; Sean V Tavtigian; Dmitry R Pruss; Gregory C Critchfield Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Katja Goldflam; Kelly K Hunt; Jeffrey E Gershenwald; S Eva Singletary; Nadeem Mirza; Henry M Kuerer; Gildy V Babiera; Frederick C Ames; Merrick I Ross; Barry W Feig; Aysegul A Sahin; Banu Arun; Funda Meric-Bernstam Journal: Cancer Date: 2004-11-01 Impact factor: 6.860
Authors: S R Lakhani; J Jacquemier; J P Sloane; B A Gusterson; T J Anderson; M J van de Vijver; L M Farid; D Venter; A Antoniou; A Storfer-Isser; E Smyth; C M Steel; N Haites; R J Scott; D Goldgar; S Neuhausen; P A Daly; W Ormiston; R McManus; S Scherneck; B A Ponder; D Ford; J Peto; D Stoppa-Lyonnet; Y J Bignon; J P Struewing; N K Spurr; D T Bishop; J G Klijn; P Devilee; C J Cornelisse; C Lasset; G Lenoir; R B Barkardottir; V Egilsson; U Hamann; J Chang-Claude; H Sobol; B Weber; M R Stratton; D F Easton Journal: J Natl Cancer Inst Date: 1998-08-05 Impact factor: 13.506
Authors: Sining Chen; Edwin S Iversen; Tara Friebel; Dianne Finkelstein; Barbara L Weber; Andrea Eisen; Leif E Peterson; Joellen M Schildkraut; Claudine Isaacs; Beth N Peshkin; Camille Corio; Leoni Leondaridis; Gail Tomlinson; Debra Dutson; Rich Kerber; Christopher I Amos; Louise C Strong; Donald A Berry; David M Euhus; Giovanni Parmigiani Journal: J Clin Oncol Date: 2006-02-20 Impact factor: 44.544
Authors: Timothy R Rebbeck; Tara Friebel; Henry T Lynch; Susan L Neuhausen; Laura van 't Veer; Judy E Garber; Gareth R Evans; Steven A Narod; Claudine Isaacs; Ellen Matloff; Mary B Daly; Olufunmilayo I Olopade; Barbara L Weber Journal: J Clin Oncol Date: 2004-02-23 Impact factor: 44.544
Authors: Shoshana M Rosenberg; Kathryn J Ruddy; Rulla M Tamimi; Shari Gelber; Lidia Schapira; Steven Come; Virginia F Borges; Bryce Larsen; Judy E Garber; Ann H Partridge Journal: JAMA Oncol Date: 2016-06-01 Impact factor: 31.777
Authors: Jada G Hamilton; Margaux C Genoff; Melissa Salerno; Kimberly Amoroso; Sherry R Boyar; Margaret Sheehan; Megan Harlan Fleischut; Beth Siegel; Angela G Arnold; Erin E Salo-Mullen; Jennifer L Hay; Kenneth Offit; Mark E Robson Journal: Breast Cancer Res Treat Date: 2017-02-01 Impact factor: 4.872
Authors: Shenin A Dettwyler; Darcy L Thull; Priscilla F McAuliffe; Jennifer G Steiman; Ronald R Johnson; Emilia J Diego; Phuong L Mai Journal: Breast Cancer Res Treat Date: 2022-05-21 Impact factor: 4.872
Authors: Megan E Tesch; Shoshana M Rosenberg; Laura C Collins; Julia S Wong; Laura Dominici; Kathryn J Ruddy; Rulla Tamimi; Lidia Schapira; Virginia F Borges; Ellen Warner; Steven E Come; Ann H Partridge Journal: Ann Surg Oncol Date: 2022-08-12 Impact factor: 4.339
Authors: Nisreen Elsayegh; Jessica Profato; Angelica M Gutierrez Barrera; Heather Lin; Henry M Kuerer; Can Ardic; Jennifer K Litton; Debasish Tripathy; Banu K Arun Journal: J Cancer Date: 2015-05-23 Impact factor: 4.207
Authors: Claire Kim; Laurel Liang; Frances C Wright; Nicole J Look Hong; Gary Groot; Lucy Helyer; Pamela Meiers; May Lynn Quan; Robin Urquhart; Rebecca Warburton; Anna R Gagliardi Journal: Breast Cancer Res Treat Date: 2017-12-23 Impact factor: 4.872